Roflumilast to Treat Cognitive Sequela After Stroke
- Sponsor
- Maastricht University
- Study ID
- NCT04854811
- Phase
- PHASE2
- Status
- Completed
Conditions
- Cerebrovascular Disorders
- Drug Intervention
- Functional Recovery
- Memory
Eligibility Criteria
- Sex
- ALL
- Age
- 41 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Roflumilast Oral Tablet — DRUGOnce daily for 12 weeks
Study Details
The aim of the current project is to validate the effects of chronic rolflumilast treatment (12 weeks) on cognitive functions (i.e. episodic memory) by means of behavioral tasks, in people suffering from cognitive impairments at least 1 year after stroke. Secondarily, the effects of roflumilast on daily activities and well-being will be assessed.
Key Dates
- Start date
- Jul 7, 2021
- Status verified
- Jan 2024
- Primary completion
- Dec 1, 2023
- Completion
- Dec 1, 2023
Study Design
- Enrollment
- 100 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboPlacebo oral capsule, once daily for 12 weeks
- Experimental: Roflumilast (100 microgram)once daily for 12 weeks
Primary Outcome Measure
Verbal Learning Test (VLT) Verbal Learning Test (VLT) (15 words) (delayed recall) [ Time Frame: Change from baseline to 12 weeks of chronic intake ] Verbal Learning Test (VLT) [ Time Frame: Change from baseline to 12 weeks of chronic intake ]
Related Studies
- Brain, Blood And Clot or Tissue Registry And CollaborationRecruiting · Justin Fraser · Lexington, Kentucky
- Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental HealthRecruiting · University of Florida · Gainesville, Florida
- Home Sleep Therapy for Older Adults With MCIRecruiting · Brain Electrophysiology Laboratory Company · Winston-Salem, North Carolina
- Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical ThrombectomyPHASE1 · Recruiting · Wake Forest University Health Sciences · Charlotte, North Carolina